Healthcare · Pharmaceuticals & Biotechnology
QVM read Mixed signals Quality Moderate, Valuation Fairly Valued, Momentum Neutral
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Ranks #168 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 4 Mar 2025 | SANJAY P PARIKH | Bulk | Buy | 30,000 | 19.3500 | BSE |
| 4 Mar 2025 | KAVITA PARIKH | Bulk | Buy | 30,000 | 19.1200 | BSE |
| 4 Mar 2025 | SAMTA POLYMERS LTD | Bulk | Buy | 44,820 | 17.5100 | BSE |
| 4 Mar 2025 | MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED | Bulk | Sell | 45,155 | 17.5100 | BSE |
| 4 Mar 2025 | MANASA REDDY DEVIREDDY | Bulk | Buy | 49,998 | 17.5100 | BSE |
| 4 Feb 2025 | GREEN PEAKS ENTERPRISES LLP | Bulk | Buy | 47,656 | 30.8800 | BSE |
| 3 Feb 2025 | DEEPIKAJINDAL | Bulk | Buy | 26,276 | 29.1000 | BSE |
| 3 Feb 2025 | RIGHT TIME CONSULTANCY SERVICE PRIVATE LIMITED | Bulk | Sell | 35,000 | 30.2800 | BSE |
| 3 Feb 2025 | SUDHANSHU KANDA | Bulk | Buy | 50,000 | 30.2800 | BSE |
| 3 Feb 2025 | GREEN PEAKS ENTERPRISES LLP | Bulk | Sell | 59,000 | 29.1000 | BSE |
Bonuses, splits, buybacks and other events. Dividends are listed separately above.
| Ex-date | Type | Subject |
|---|---|---|
| — | NAME_CHANGE | Name changed from YENKEY DRUGS & PHARMACEUTICALS LTD. to Venmax Drugs And Pharmaceuticals Ltd |
Exchange disclosures (NSE and BSE), most recent first.
| Date | Category | Announcement |
|---|---|---|
| 28 Sep 2026 | AGM/EGM | Venmax Drugs and Pharmaceuticals Ltd - 531015 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report |
| 25 Sep 2026 | Insider Trading / SAST | Venmax Drugs and Pharmaceuticals Ltd - 531015 - Closure of Trading Window |
| 8 Sep 2026 | Company Update | Venmax Drugs and Pharmaceuticals Ltd - 531015 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement |
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Board of directors and corporate information →
Data unavailable (no single-stock futures or options activity on record for this company).
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
